派林生物(000403) - 2024 Q1 - 季度财报

Financial Performance - Revenue for Q1 2024 reached ¥435,640,719.29, a 67.00% increase compared to ¥260,860,262.39 in the same period last year[4] - Net profit attributable to shareholders was ¥121,948,626.85, reflecting a 116.31% increase from ¥56,376,087.53 year-over-year[4] - Net profit excluding non-recurring items was ¥107,604,743.39, up 196.85% from ¥36,249,382.73 in the previous year[4] - Basic earnings per share increased to ¥0.1669, a rise of 116.47% compared to ¥0.0771 in the same quarter last year[4] - The total operating revenue for Q1 2024 was CNY 435,640,719.29, a significant increase of 67% compared to CNY 260,860,262.39 in the same period last year[15] - The net profit for Q1 2024 reached CNY 121,869,775.56, compared to CNY 56,218,316.92 in Q1 2023, representing a growth of 117%[16] - The total comprehensive income for the first quarter was approximately CNY 121.87 million, compared to CNY 56.21 million in the same period last year, representing an increase of 116.5%[17] - Basic and diluted earnings per share for the first quarter were both CNY 0.1669, up from CNY 0.0771 in the previous year, indicating a growth of 116.5%[17] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥8,717,806,952.95, a slight increase of 1.01% from ¥8,630,474,084.53 at the end of the previous year[4] - The company's total assets increased to CNY 8,717,806,952.95 from CNY 8,630,474,084.53, marking a growth of approximately 1.01%[15] - Non-current liabilities rose to CNY 314,161,424.24, up from CNY 286,415,637.35, indicating a 9.7% increase[15] - The total equity attributable to shareholders increased to CNY 7,551,538,502.25 from CNY 7,428,649,258.06, showing a growth of approximately 1.65%[15] - The company’s goodwill remained stable at CNY 2,614,611,614.12, unchanged from the previous period[15] Cash Flow - Cash flow from operating activities showed a net outflow of ¥51,862,351.40, a decrease of 148.67% compared to a net inflow of ¥106,564,727.56 in the same period last year[4] - Cash inflow from operating activities totaled CNY 564.47 million, slightly up from CNY 562.86 million year-over-year[19] - Cash outflow from operating activities increased to CNY 616.34 million from CNY 456.29 million, resulting in a net cash flow from operating activities of -CNY 51.86 million, down from CNY 106.56 million last year[19] - The ending balance of cash and cash equivalents was CNY 987.65 million, slightly up from CNY 973.24 million at the end of the previous year[20] - The company received CNY 31.50 million in other cash related to operating activities, an increase from CNY 17.50 million year-over-year[19] Expenses and Investments - Total operating costs amounted to CNY 297,485,500.88, up from CNY 218,309,593.81, reflecting a 36% increase year-over-year[16] - Research and development expenses rose to ¥20,864,588.50, an increase of 46.17% from ¥14,274,385.64 year-over-year, indicating a focus on innovation[7] - Research and development expenses for the quarter were CNY 20,864,588.50, compared to CNY 14,274,385.64, reflecting a 46% increase year-over-year[16] - Investment income surged to ¥8,645,797.49, a dramatic increase of 1301.96% from ¥616,694.45 in the previous year[7] - The company reported an investment income of CNY 8,645,797.49, a significant increase from CNY 616,694.45 in the previous year[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,188[9] - The largest shareholder, Qiongcheng Shengbang Yinghao Investment Partnership, holds 20.98% of shares, totaling 153,752,812 shares[9] - The top ten shareholders include several entities with significant stakes, such as Harbin Tongzhi Cheng Technology Development Co., holding 10.97%[9] Strategic Initiatives - The company has engaged in strategic cooperation agreements and plans to utilize idle funds for financial management in 2024[11] - The report includes announcements regarding the completion of stock repurchase and the lifting of restrictions on certain shares[11] - The company is actively pursuing market expansion and has obtained a license for single plasma collection[11] Other Operating Metrics - The company reported a significant increase in contract liabilities, which rose by 53.70% to ¥16,543,720.51, reflecting higher prepayments from customers[7] - The company experienced a 3121.51% increase in other operating expenses, totaling ¥8,272,232.99, primarily due to increased donations[7] - The company's cash and cash equivalents decreased from 1,429,349,951.47 CNY to 988,509,109.12 CNY, a decline of approximately 30.9%[13] - The total current assets increased slightly from 3,426,074,653.60 CNY to 3,441,910,520.51 CNY, an increase of about 0.5%[13] - Inventory rose significantly from 909,374,530.76 CNY to 1,104,864,882.11 CNY, reflecting an increase of approximately 21.5%[13] - The company has a long-term receivable of 600,000,000.00 CNY, unchanged from the previous period[13]